

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vigonvita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON MARCH 19, 2026

Reference is made to the notice of the extraordinary general meeting (the “**EGM**”) and the circular (the “**Circular**”) of Vigonvita Life Sciences Co., Ltd. (the “**Company**”) dated March 2, 2026. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Circular. The board (the “**Board**”) of directors (the “**Director(s)**”) of Vigonvita Life Sciences Co., Ltd. (the “**Company**”) is pleased to announce that the EGM was held at 8th Floor, Building A, No. 108, Yuxin Road, Suzhou Industrial Park District, Suzhou, PRC at 10:00 a.m. on Thursday, March 19, 2026.

As at the date of the EGM, the total number of the issued Shares of the Company was 167,597,800 Shares, comprising 100,920,667 Unlisted Shares and 66,677,133 H Shares. The Company did not hold any treasury Shares or repurchased Shares pending cancellation. Accordingly, the total number of Shares entitling the holders to attend and vote on resolution were 167,597,800 Shares, representing 100% of the total issued Shares of the Company.

ATTENDANCE AT THE EGM

The Board comprises 6 members, all of whom attended the EGM in person or by electronic means. Supervisors and senior management of the Company were also present at the EGM.

The Shareholders or authorized proxies of the Shareholders attending the EGM held an aggregate of 121,990,751 Shares with voting rights in aggregate, representing approximately 72.79% of the total issued Shares of the Company. Voting at the EGM was conducted by way of poll. The EGM was convened and held in accordance with the applicable PRC laws and regulations, the Listing Rules and the Articles of Association.

(i) There were no restrictions on any Shareholders to cast votes on any of the proposed resolution at the EGM; (ii) no Shareholder was required under the Listing Rules to abstain from voting on the proposed resolution at the EGM; (iii) there were no Shares entitling the holders to attend and abstain from voting in favor of the proposed resolution at the EGM as required by Rule 13.40 of the Listing Rules; and (iv) no party stated any intention in the Circular to vote against or abstain from voting on the proposed resolution at the EGM.

Computershare Hong Kong Investor Services Limited (the H Share Registrar of the Company) acted as the scrutineer for the vote-taking at the EGM.

POLL RESULTS OF THE EGM

All resolution proposed at the EGM were voted by registered poll. The poll results were as follows:

Special resolution		Number of votes (Percentage of the total voting Shares at the EGM)			Passed by Shareholders
		For	Against	Abstain	Yes
1.	To consider and approve the adoption of the H Share Award Scheme and to approve the authorization to the Board to handle matters pertaining to the H Share Award Scheme.	121,990,751 (100%)	0 (0%)	0 (0%)	

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the resolution above, such resolution was duly passed as a special resolution at the EGM.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, March 19, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.